stockportfolio.pro
Denali Therapeutics Inc. (DNLI)
Healthcare · Biotechnology · NasdaqGS
Denali Therapeutics Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $129.16M | $26.68M | $335.66M | $48.66M | $108.46M | $330.53M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-86.65M | $-88.19M | $-36.24M | $-197.61M | $71.14M | $-290.58M | $-325.99M | $-145.22M | $-422.77M | $-512.54M |
| Net margin | — | — | -28.1% | -740.7% | 21.2% | -597.2% | -300.6% | -43.9% | — | — |
Source: Denali Therapeutics Inc. SEC filings (10-K).
Explore 10 years of Denali Therapeutics Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track DNLI in your portfolio →
Denali Therapeutics Inc. financial history by metric
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc. — frequently asked questions
What is Denali Therapeutics Inc.'s revenue?
Denali Therapeutics Inc. (DNLI) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Denali Therapeutics Inc. profitable?
No — DNLI reported a net loss of $-512.54M in fiscal 2025.
What is DNLI's P/E ratio?
Denali Therapeutics Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Denali Therapeutics Inc. have?
As of fiscal year 2025, DNLI carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Denali Therapeutics Inc.'s market cap?
Denali Therapeutics Inc. (DNLI) has a market capitalization of about $3.29B, based on the latest data in our nightly-refreshed cache.
When does Denali Therapeutics Inc.'s fiscal year end?
DNLI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Denali Therapeutics Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.